Dr. Robert A. Nagourney, MD
Breakthrough for Young Patients with a Rare Form of Liver Cancer
Extremely rare liver cancer that mostly affects people in their twenties associated with a gene rearrangement, mostly lethal, until now.
top of page
Nagourney Cancer Blog
Dr. Robert A. Nagourney, MD
- May 19
- 3 min
For Medical Oncology, Déjà Vu All Over Again
Patients are being encouraged to contact the researchers to get biopsies and help take charge of their disease.
Dr. Robert A. Nagourney, MD
- May 15
- 4 min
Nagourney Cancer Institute: 20-year Experience in 10,000 Patients
At the 2023 American Association for Cancer Research meeting in Orlando, we reported results of ex vivo analysis of programmed cell death.
Dr. Robert A. Nagourney, MD
- Mar 27
- 2 min
Benefits of Combining Functional Profiling with Nagourney Cancer Institute's 11,000 Patient Studies
Combining Functional Profiling with Nagourney Cancer Institute's 11,000 patient studies provides personalized cancer treatment plans.
Dr. Robert A. Nagourney, MD
- Mar 2
- 3 min
Cancer Patients Do Not Need to Take No for an Answer
Cancer patients must take charge of their disease. If they are well, regardless of their condition, they should look for options.
Dr. Robert A. Nagourney, MD
- Feb 15
- 2 min
Functional Profiling vs. Functional Medicine: What’s the Difference?
We take a different approach to the treatment of cancer – based on profiling how our patients’ cancerous cells will respond to treatment.
Dr. Robert A. Nagourney, MD
- Jan 30
- 3 min
Treatment for Stage 4 Pancreatic Cancer May Be at Hand
After the recommended treatment, FOLFIRINOX, using his tissue we suggested new classes of drugs that target P53 and MEK/ERK.
Dr. Robert A. Nagourney, MD
- Dec 30, 2022
- 2 min
A Year-End Reflection
2022 Reflection. Among our most important accomplishments in 2022 was the installation of a world-class Mass Spectrometry research program.
Dr. Robert A. Nagourney, MD
- Nov 29, 2022
- 2 min
Lung Cancer Patients Need More Than a Lungmap to Nowhere
I applaud anything that accelerates clinical development, but once again the focus is almost exclusively genomic.
Dr. Robert A. Nagourney, MD
- Nov 2, 2022
- 2 min
Is The Role Of The Oncologist To Add Drugs or Subtract Drugs?
Over time I came to realize that the role of the infectious disease expert was not to add antibiotics but to subtract them.
Dr. Robert A. Nagourney, MD
- Oct 17, 2022
- 3 min
Do Rare Tumors Hold The Key To Future Cancer Cures?
Can rare tumors offer the way forward? This optimism comes from the fact that not unlike CML, rare cancers may carry unique insights.
Dr. Robert A. Nagourney, MD
- Oct 13, 2022
- 2 min
Fibrolamellar Cancer Foundation Symposium September 29, 2022
Fibrolamellar cancer (FLC) is a rare tumor of adolescents and young adults occurring 1 in 5 million that arises as a large mass in the live
bottom of page